Bradley introduces first new topical wart treatment in ten years

FAIRFIELD, N.J. Bradley Pharmaceuticals today announced the launch of its new drug, Veregen ointment 15%. The drug is used as a topical treatment for external genital and perianal warts in patients 18 years and older.

Veregen is the first botanical drug approved for prescription use in the U.S. and is patented through 2017, with additional applications pending which, if approved, would extend patents beyond 2020. The active ingredient in Veregen is sinecatechins, a proprietary mixture of 8 catechins, the primary phenols found in green tea leaves. Veregen is the first new prescription treatment for external genital warts in ten years.

In two Phase III studies, Veregen proved effective in clearing both baseline and newly emerging external genital and perianal warts, with complete clearance in 53.6 percent of all patients studied who received Veregen. Veregen also demonstrated low recurrence rates during these trials. When treated with Veregen, only 6.8 percent of the patients experienced recurrence.

External genital warts are one of the most common and fastest spreading venereal diseases worldwide. More than 1 million new cases are seen each year in the U.S. and nearly 1.4 million sexually active adults have visible genital warts at any point in time.

The drug will begin shipping to wholesalers and will be available in drugstores within a few weeks.